Clinical Characteristics and Management of Checkpoint Inhibitor Pneumonitis in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Immunotherapy
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2024.10.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Long Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: dylan919…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: Neoadjuvant immunotherapy with checkpoint inhibitors has shown promising results for non-small-cell lung cancer (NSCLC) patients. However, it has been associated with immune-related adverse events (irAEs), including checkpoint inhibitor pneumonitis (CIP), which can be life-threatening. METHODS: This retrospective study analysed the medical records of 197 NSCLC patients who underwent neoadjuvant checkpoint inhibitor therapy to investigate the incidence, clinical characteristics, and management of CIP. RESULTS: Of the 197 patients, 24 (12.2%) developed CIP. The majority of patients presented with respiratory symptoms, and ground-glass opacities were the most common radiographic finding. Patients with CIP had a longer duration of immunotherapy and a higher baseline C-reactive protein level than those without CIP. Most cases were mild to moderate in severity (Grade 1: 11, Grade 2: 6, Grade 3: 5) and managed with corticosteroids, while 2 patients of Grade 4 developed severe respiratory failure requiring mechanical ventilation. No patient died due to respiratory failure. CONCLUSIONS: CIP was identified as a potential complication of neoadjuvant treatment with checkpoint inhibitors in patients with resectable NSCLC. Therefore, close monitoring for CIP and prompt recognition and management of symptoms are essential for the safe use of checkpoint inhibitors in NSCLC patients. While the study also found that such neoadjuvant treatment can induce a major pathological response in a significant proportion of these patients, further research is required to fully understand and manage the risk factors of CIP in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: dylan919@139.com.
- Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Shanghai Institute of Digestive Disease, Shanghai, China; State Key Laboratory for Oncogen…
- Department of Thoracic Surgery, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
- Department of Anesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Thoracoabdominal department оf Moscow Oncology Research Institute named after P. Hertsen-branch of Federal State Budgetary Institution "National Medical Research Radiological Centre" of the Ministry of Health of the Rus…
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Jiang, L., Jiang, S., Miao, W., Shen, Y., Bolotina, L., Zhu, H., Zou, N., Tian, Y., Pan, H., Huang, J., Ryabov, A., & Luo, Q. (2025). Clinical Characteristics and Management of Checkpoint Inhibitor Pneumonitis in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Immunotherapy. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.10.012
Vancouver
Jiang L, Jiang S, Miao W, Shen Y, Bolotina L, Zhu H, et al. Clinical Characteristics and Management of Checkpoint Inhibitor Pneumonitis in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Immunotherapy. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2024.10.012
BibTeX
@article{Jiang2025,
author = {Jiang, Long and Jiang, Shanshan and Miao, Wang and Shen, Yaofeng and Bolotina, Larisa and Zhu, Hongda and Zou, Ningyuan and Tian, Yu and Pan, Hanbo and Huang, Jia and Ryabov, Andrey and Luo, Qingquan},
title = {Clinical Characteristics and Management of Checkpoint Inhibitor Pneumonitis in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Immunotherapy},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2024.10.012}
}
EUVIMED